Study on the Safety and Effects of Telisotuzumab Vedotin for Previously Treated Non-Squamous Non-Small Cell Lung Cancer

Inclusion Criteria

• Expected to live at least 12 more weeks.
• Have non-small cell lung cancer (NSCLC) with high levels of a protein called c-Met.
• Cancer must be advanced or have spread to other parts of the body.
• Must know the status of a specific gene mutation called EGFR.
• Other gene changes that can be targeted by treatment are allowed.
• Must have cancer that can be measured by standard criteria.
• Must be in good general health, able to carry out normal activities or light work.
• Have had no more than one previous chemotherapy treatment for advanced cancer.
• Cancer must have worsened after at least one previous treatment for advanced NSCLC.

Exclusion Criteria

• Have a type of lung cancer with certain specific features, like adenosquamous or neuroendocrine types.
• Have specific EGFR gene mutations that can be targeted by treatment.
• Have previously received treatments targeting c-Met or similar drugs.
• Have had previous treatment with a drug called docetaxel.
• Have cancer that has spread to the brain or spinal cord unless it has been treated.
• Have a history of other cancers, unless specified in the study.
• Have certain lung conditions or active lung inflammation.
• Have unresolved significant side effects from previous cancer treatments, except for hair loss or anemia.
• Have had major surgery within the last 21 days.
• Have significant health conditions, including liver disease or alcohol abuse.
• Have significant swelling, fluid buildup, or nerve problems.
• Have an active, uncontrolled infection.
• Have an active eye disorder affecting the cornea.